British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, with Statements for UK Practice
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Background: Testosterone deficiency (TD) is an increasingly common problem with significant health implications, but its diagnosis and management can be challenging. Aim: To review the available literature on TD and provide evidence-based statements for UK clinical practice. Methods: Evidence was derived from Medline, EMBASE, and Cochrane searches on hypogonadism, testosterone (T) therapy, and cardiovascular safety from May 2005 to May 2015. Further searches continued until May 2017. Outcomes: To provide a guideline on diagnosing and managing TD, with levels of evidence and grades of recommendation, based on a critical review of the literature and consensus of the British Society of Sexual Medicine panel. Results: 25 statements are provided, relating to 5 key areas: screening, diagnosis, initiating T therapy, benefits and risks of T therapy, and follow-up. 7 statements are supported by level 1, 8 by level 2, 5 by level 3, and 5 by level 4 evidence. Clinical Implications: To help guide UK practitioners on effectively diagnosing and managing primary and age-related TD. Strengths and Limitations: A large amount of literature was carefully sourced and reviewed, presenting the best evidence available at the time. However, some statements provided are based on poor-quality evidence. This is a rapidly evolving area of research and recommendations are subject to change. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions and take personal values and preferences and individual circumstances into account. Many issues remain controversial, but in the meantime, clinicians need to manage patient needs and clinical expectations armed with the best clinical evidence and the multidisciplinary expert opinion available. Conclusion: Improving the diagnosis and management of TD in adult men should provide somatic, sexual, and psychological benefits and subsequent improvements in quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 2×
“In obese men, the free androgen index, calculated as TT/SHBG 100, is used by some laboratories but we recommend the calculated FT derived from SHBG and albumin through the equation of Vermeulen et al.(121) An online FT calculator and downloadable app, sponsored by the Primary Care Testosterone Advisory Group, can be f…”
MethodBhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954 · cited 3×
“Combined primary and secondary TD, sometimes known as mixed TD, is associated with low T levels, impaired spermatogenesis, and variable FSH and LH levels, depending on whether primary or secondary testicular failure predominates.(22) Combined primary and secondary TD occurs with certain conditions such as sickle cell…”
BackgroundInfluentialGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544 · cited 1×
“22 nmol/L]).(8) However, 75% of men maintained normal T levels into old age, suggesting that TD is not merely a function of aging.”
BackgroundAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman, J. M., & Vermeulen, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0013 · Cited by 1,079
Vigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967
Effects of Testosterone Treatment in Older Men
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506119 · Cited by 890
Prevalence of hypogonadism in males aged at least 45 years: the HIM study
MULLIGAN, T., FRICK, M. F., ZURAW, Q. C., STEMHAGEN, A., & MCWHIRTER, C. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.00992.x · Cited by 767 · cited 1×
“20 for lower urinary tract symptoms related to benign prostatic hyperplasia.(32) Significant TD is associated with an increased risk of chronic anemia and osteoporosis.”
Background
Cited by
Agarwal, A., Baskaran, S., Parekh, N., Cho, C.-L., Henkel, R., Vij, S., Arafa, M., Panner Selvam, M. K., & Shah, R. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32667-2 · Cited by 1,284
Paediatric and adult-onset male hypogonadism
Salonia, A., Rastrelli, G., Hackett, G., Seminara, S. B., Huhtaniemi, I. T., Rey, R. A., Hellstrom, W. J. G., Palmert, M. R., Corona, G., Dohle, G. R., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0087-y · Cited by 286
Self-citationMale Obesity-related Secondary Hypogonadism – Pathophysiology, Clinical Implications and Management
Fernandez, C. J., Department of Endocrinology & Metabolism, P. H., Chacko, E. C., Department of Endocrinology, J. G. H., Pappachan, J. M., & Department of Endocrinology & Metabolism, L. T. H. N. F. T. (2019) · European Endocrinology · doi:10.17925/ee.2019.15.2.83 · Cited by 145
“Diagnostic recommendations based on British Society for Sexual Medicine guidelines are shown in Table 1.(50)”
MethodNovel Therapy for Male Hypogonadism
Carrasquillo, R., Chu, K., & Ramasamy, R. (2018) · Current Urology Reports · doi:10.1007/s11934-018-0816-x · Cited by 31
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism
Huhtaniemi, I. T., & Wu, F. C. W. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101622 · Cited by 31
Kolind, M. I., Christensen, L. L., Caserotti, P., Andersen, M. S., & Glintborg, D. (2022) · Andrology · doi:10.1111/andr.13147 · Cited by 12
“represent less specific symptoms and signs.(6,7) A recent review estimated that the risk of hypogonadism ranged from 19 to 86% in men treated with opioids, depending on drug dose and treatment duration, and the applied cut point for TT used to define male hypogonadism.”
BackgroundInfluential
Metadata
- Authors
- Hackett, G., Kirby, M., Edwards, D., Jones, T. H., Wylie, K., Ossei-Gerning, N., David, J., & Muneer, A.
- Venue
- The Journal of Sexual Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-12-01
- Volume
- 14
- Issue
- 12
- Pages
- 1504-1523
- ISSN
- 1743-6095 (ISSN-L)
- 1743-6109
- OpenAlex
- W2774513630
- Cited by
- 143
- References
- 43
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.